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Abstract
In this work we propose and investigate a family of models, which admits as particular cases
some well known mathematical models of tumor-immune system interaction, with the additional
assumption that the influx of immune system cells may be a function of the number of cancer
cells. Constant, periodic and impulsive therapies (as well as the non-perturbed system) are inves-
tigated both analytically for the general family and, by using the model by Kuznetsov et al. (V.
A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson. Nonlinear dynamics of immuno-
genic tumors: Parameter estimation and global bifurcation analysis. Bulletin of Mathematical
Biology,56(2) 295-321, (1994)), via numerical simulations. Simulations seem to show that the
shape of the function modeling the therapy is a crucial factor only for very high values of the
therapy period T , whereas for realistic values of T , the eradication of the cancer cells depends on
the mean values of the therapy term. Finally, some medical inferences are proposed.
Keywords: Cancer – Immunotherapy – Stability Theory – Periodical forcing
1 Introduction
Millions of people die from cancer every year [1]. And worldwide trends indicate that millions more will
die from this disease in the future [2]. Great progress has been achieved in fields of cancer prevention
and surgery and many novel drugs are available for medical therapies [3, 4, 5]. Biophysical models
may prove to be useful in oncology not only in explaining basic phenomena [6, 7], but also in helping
clinicians to better and more scientifically plan the schedules of the therapies [7, 8]. An interesting
therapeutic approach is immunotherapy [4, 5], consisting in stimulating the immune system in order
to better fight, and hopefully eradicate, a cancer. In particular, in this paper I will be referring to
generic immunostimulations, for example via cytokines, but for the sake of simplicity I will use the
term ”immunotherapy”. The basic idea of immunotherapy is simple and promising, but the results
obtained in medical investigations are globally controversial [9, 10, 11, 12], even if in recent years
there has been evident progress. From a theoretical point of view, a large body of research has been
devoted to mathematical models of cancer-immune system interactions and to possible applications
to cure the disease [13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24] (and references therein). Analyzing the
best known finite dimensional models [13, 14, 16, 20, 23], we note that their main features are the
following:
• Existence of a tumor free equilibrium;
• Depending on the values of parameters, there is the possibility that the tumor size may tend to
+∞ or to a macroscopic value;
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• Possible existence of a ”small tumor size” equilibrium, which coexists with the tumor free equi-
librium.
An ”accessory” feature is the existence of limit cycles [16]. From this rough summary, one may
understand that the puzzling results obtained up to now by immunotherapy [9] may be strictly linked
to the complex dynamical properties of the immune system-tumor competition. In general, it happens
that the cancer-free equilibrium coexists with other stable equilibria or with unbounded growth, so
that the success of the cure depends on the initial conditions, and - even theoretically - it is not always
granted.
2 A general family of models and its properties
In [22], Sotolongo-Costa et al. proposed the following very interesting Volterra-like model (similar to
the one in [20]) for the interaction between a population of tumor cells (whose number is denoted by
X) and a population of lymphocyte cells (Y ) :
X ′ = aX − bXY (1)
Y ′ = dXY − fY − kX + u+ P (t), (2)
where the tumor cells are supposed to be in exponential growth (which is, however, a good approxi-
mation only for the initial phases of the growth) and the presence of tumor cells implies a decrease of
the ”input rate” of lymphocytes. System (1)-(2) may be rewritten in non-dimensional form [22]:
x′ = αx− xy (3)
y′ = xy − 1
α
y − kx+ σ + p(t) (4)
(in short notation (x′, y′) = C(x, y)). The function p(t) ≥ 0 is assumed periodic with period T and it
models the effect of immunotherapy. The model has been studied in depth both in the case of absence
of therapy and in the case of therapy by using the test function p(t) = 0.5F (1 + cos(4piνt)).
The model shows two equilibria (one of which is tumor-free) and also unbounded growth. However,
the system (3)-(4) allows negative solutions for non small x, which is not physically acceptable. In
fact:
C(x, 0) = (ax, σ + p(t)− kx) (5)
implies that for x > (σ + pmax)/k it is C(x, 0).(0,−1) > 0, and y(t) becomes negative in finite times.
Furthermore, the second equilibrium point is a consequence of the negativity of σ − kx.
The model in [22], though it has this problem of lack of physical consistency, is, however, of great
interest because the killing of lymphocytes is seen as function of the x variable Alternatively, the influx
of lymphocytes may be thought of as a function of the entity of the disease, which we will denote
as Q(x). Indeed, it has been observed that in some cases cancer progression may cause generalized
immunosuppression. See [25] and references therein. See [25] and references therein. Thus, in [22] it
is Q(x) = σ(1− (k/σ)x), which may be read as a first order Taylor approximation of a more general
non-increasing function.
However a general influx function is only one of the possible modifications of model (3)-(4): there
may be others, which are also biologically reasonable. One might take into the account many factors:
different functional forms for the interaction term, saturation in the predation term and, mainly,
non exponential growth of the cancer: logistic, gompertzian, generalized logistic etc . . . All these
modifications are reasonable and useful. Thus, I think that it might be useful to define and study the
following general family of models:
x′ = x(αf(x)− φ(x)y) (6)
y′ = β(x)y − µ(x)y + σq(x) + θ(t) (7)
where:
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• x and y are the non-dimensionalized numbers of, respectively, tumor cells and of effectors cells
of immune system;
• 0 < f(0) ≤ +∞, f ′(x) ≤ 0 and in some relevant cases we shall suppose that it exists an
0 < x ≤ +∞ such that f(x) = 0), Limx→0+xf(x) = 0. Thus, f(x) summarizes many widely
used models of tumor growth rates, such as the Exponential model: f(x) = 1 [7], the Gompertz:
: f(x) = Log(A/x) [7, 50] and its generalizations [7, 50], the Logistic model: f(x) = 1 − x/A
[50], the Hart-Schochat-Agur: f(x) = x−γ , 0 < γ < 1 [26], the von Bertanlaffy: f(x) = x−1/3−b
[50, 53], the Guiot’s et al. model: f(x) = x3/4 − b [27], the linear growth model by Bru and
coworkers[28] which may be written as follows: f(x) = x−1/3 (note that it may be considered a
particular case of the von Bertalaffy model and of the Hart-Shochat-Agur model) etc. . .
• φ(x) > 0, φ(0) = 1, φ′(x) ≤ 0 and xφ(x)→ l ≤ +∞;
• q(x) is such that q(0) = 1 (as a consequence σ = Q(0)) and it may be non-increasing or also
initially increasing and then decreasing, i.e. we may assume that either the growth of tumor
decreases the influx of immune cells or that, on the contrary, it initially stimulates the influx);
• β(x) ≥ 0, β(0) = 0 and β′(x) ≥ 0;
• µ(x) > 0 and µ′(x) > 0.
For the sake of simplicity we define the following function Ψ(x) = µ(x)− β(x) and write:
x′ = x(αf(x)− φ(x)y) (8)
y′ = −Ψ(x)y + σq(x) + θ(t). (9)
Ψ(x) is assumed to be positive, otherwise it may be positive in [0, x1) ∪ (x2,+∞) with Ψ(x1) =
Ψ(x2) = 0. We may assume that it has an absolute minimum in [0,+∞). We may use Ψ(x) to classify
the tumors depending on their degree of aggressiveness against the immune system:
• Ψ(x) > 0: in such a case the ability of destroying immune cells is never won by the stimulatory
effect on the immune system, therefore the tumor may be indicated as ”highly aggressive”/”lowly
immunogenic”;
• Variable sign Ψ(x): since in such a case the destruction of cells may be compensated by the
stimulatory effect, we will refer to such a tumors as ”lowly aggressive”/”highly immunogenic”.
The above model includes as particular cases the models [13, 14, 20, 23]. For instance, the
Stepanova model [13] is such that f(x) = 1, φ(x) = 1, β(x) = β1x, q(x) = 1 and µ(x) = µo + µ2x
2;
the de Vladar-Gonzalez model [23] is similar, but: f(x) = Log(K/x).
Note that Nani and Freedman proposed an interesting model of adoptive cellular immunotherapy
in which generic functions are used [19]. However, their approach differs from ours since in their model
the proliferation of cells of the immune systems is not stimulated by cancer cells. In other words in
the Nani and Freedman model the interaction tumor cells - immune system is only destructive for
immune cells. Furthermore, in their model the ”loss rates” are proportional (in our notation we might
write µ(x) = µ(0) + constφ(x)).
In the absence of treatment, system (8)-(9) admits the existence of a cancer free equilibrium
CF = (0, σ/Ψ(0)).
If f(0) < +∞, we have that if σ > σcr = αΨ(0)f(0)/φ(0) CF is locally asymptotically stable
(LAS), unstable if σ < σcr. Biologically, σ > σcr means that the immune system works very well and
that it is able to destroy small tumors. On the contrary σ ≈ 0 means that there is immunodepression.
Furthermore, when φ(x) = constant = ϕ and Ψ(x) ≤ Ψ∗ < +∞, if σ > σ∗ = αf(0)Ψ∗/(qminϕ)
it follows that CF is globally asymptotically stable (GAS). In fact, from y′ = −Ψ(x)y + σq(x) ≥
−Ψ∗y + σqmin if follows that asymptotically y(t) ≥ σqmin/Ψ∗. As a consequence, asymptotically
x′ ≤ (αf(0)− ϕ(σqmin/Ψ∗))x, i.e. if σ > σ∗ it is x(t)→ 0⇒ y(t)→ σ/Ψ(0).
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A relevant problem, up to now, is that the immunotherapeutic agents are characterized by strong
toxicity, thus σ > σ∗ might be too biologically high, even in cases in which when it is mathematically
small.
If f(0) = +∞, as in the Gompertzian case (used, for example, in [23]) and in other tumor growth
models, then CF is unstable anyway (as previously stressed for the particular model [23]) because in
such a cases the derivative of xf(x) at x = 0 is +∞. In the light of [23] and of our generalization, this
implies that the immune system would never be able to totally suppress even the smallest tumor cell
aggregates, which is a very strong inference. This instability result deserves some comments because
it has deep medical implications: the impossibility to completely recover from any type of tumors
whatsoever. On the contrary, it is commonly held that the immune system may be able, in some
cases, to kill a relatively small aggregate of cancer cells. In the background of all cancer therapies
(which are of finite duration) there is the implicit hypothesis that the drug will kill the vast majority
of the malignant cells and that the relatively few residual cells may in some cases be killed by the
immune system [32]. Accepting this hypothesis, the equilibrium CF should have the possibility to be
LAS and, as a consequence, for small x the function f(x) should be bounded.
The modeling of cancer by means of the Gompertz law of growth was introduced in early sixties by
A. K. Laird [33, 34]. She conducted pioneering data-fitting work using a vast amount of real data and
justified the law in terms of increasing mean generation time. There is much research showing that
the Gompertzian model fits data well from experimental and in vivo tumors [36, 35, 37, 38, 39, 40, 41].
From a theoretical point of view, Gyllenberg and Webb [42], Calderon and Kwembe [43], Calderon and
Afenya [44, 45] proposed physico-mathematical justification of the Gompertz model. Furthermore,
some interesting physical properties of the Gompertz model have been elucidated by Konarski and
Molski [46] and by Konarski and Waliszewski [47].
However, the doubling time of a population of cells cannot be lower than the minimal time needed
by a cell to divide, which is obviously non-null. This biological constraint is in contrast with the
unboundedness of f(x) in the Gompertz and other models, as stressed by Wheldon [7]. More recently,
inconsistency at low number of cells have been recognized by Castorina and Zappala’ in their derivation
of the Gompertizan model based on methods of statistical mechanics [48, 49]. They showed that the
validity of the Gompertz model starts above a minimum threshold for the number of cells, whereas
under the threshold there is exponential growth. In other words, they derived biophysically the Gomp-
Ex model proposed on biological ground in [54, 7]. Using data from multicellular tumor spheroids,
Marusic and coworkers performed a systematic comparison of many models [50], which showed that
Gompertz’s model fitted their data very well, but slightly less well than the Piantadosi model [55],
which has finite f(0). Furthermore, in their fittings, it was not possible to discriminate between the
pure Gompertz model and the Gomp-Ex model. Demicheli and coworkers used Gomp-Ex model on in
vitro and in vivo data obtaining results strongly supporting this model [52]. Other comparisons may
be found in [44, 53]. Moreover, in general, van Leeuwen and Zonneveld [51] claims that it may be
not possible to discriminate between exponential, logistic and gompertzian models in the early phases
of growth. Recent experimental studies conducted by Bru and coworkers support an initial phase of
exponential growth [28]. Summarizing, I consider the results by de Vladar and Gonzalez (and our
extensions) to be very valuable, but they may be read in a dichotomic way:
• A tumor is permanent: the innate immune surveillance is never able to completely eradicate
even the smallest tumor.
• Since there is relevant evidence that the immune system is able in some cases to eliminate
small tumors [57, 58] (as we will see in following sections, the ability of eradicate the disease
or not depends on initial conditions), the properties of the de Vladar-Gonzalez model (and of
our extension) may be seen as an evidence that Gompertzian and other models characterized
by f(0) = +∞ are not appropriate for very small tumors, in coherence with [7, 48, 49, 28].
In case of the absence of influx of immune cells (q(x) = 0) and for laws of growth in which x exists,
there is a different particular equilibrium point, which we shall call ”immune free”: IF = (x, 0), which
is LAS.
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Other multiple non null equilibria may be found by finding the positive intersection of the two
nullclines:
yC(x) = α
f(x)
φ(x)
(10)
yI(x) =
σq(x)
Ψ(x)
. (11)
The functions yC(x) and yI(x) are useful in the determination of the LAS of the equilibria , since the
characteristic polynomial of the Jacobian, calculated at a given equilibrium point (xe, ye), is:
λ2 +
(
Ψ(xe)− xeφ(xe)y′C(xe)
)
λ+ Ψ(xe)xeφ(xe)
(
− y′C(xe) + y′I(xe)
)
= 0. (12)
So the LAS condition is:
y′C(xe) <
Ψ(xe)
xeφ(xe)
AND y′I(xe) > y
′
C(xe). (13)
Note that the first part of the AND condition is automatically fulfilled when y′C(x) ≤ 0 (because xe
cannot lie in an interval where Ψ(x) < 0), whereas the second part has a straightforward geometrical
interpretation.
Finally, it is interesting to note that the above family of model may admit limit cycles if f(x) = 1
(exponential growth) and q(x) is identically null for x > xq with xq < x1. In fact, in such a case there
is the equilibrium point (x1, α) whose characteristic polynomial is:
λ2 + h2 = 0, h2 := −x1Ψ′(x1)α > 0 (14)
In effect, some cases of sustained oscillations (or slow oscillations with very small damping) have been
reported in the medical literature [29, 30, 31]. Periodic solutions in absence of influx of immunocom-
petent cells are predicted also in [16].
On the contrary, if y′C(x) ≤ 0 (for example when φ(x) is constant), by applying the Dulac-Bendixon
theorem with multiplicative factor 1/(xyφ(x)) (as in the specific models [14, 20]) one obtains that the
presence of limit cycles is not possible. In fact:
Div
( 1
xyφ(x)
(x′(x, y), y′(x, y))
)
=
αy′C(x)
y
− σ q(x)
xφ(x)y2
< 0 (15)
2.1 The global behavior
In some important cases, it is possible to study the global behavior of the family, by means of differ-
ential inequalities and of the Poincare-Bendixon trichotomy [56]. We may state the following simple
propositions:
1. When Ψ(x) > 0 and f(x) = 1 and y′C(x) ≥ 0, if it is yI(x) < yC(x) then x(t) → +∞. Proof:
Let us define yMAXI := Maxx∈R+yI(x) and xM such that yI(xM ) = y
MAX
I . If it is yI(x) < yC(x)
it is easy to show that the set H =
{
(x, y)|x > xM AND 0 ≤ y ≤ yMAXI
}
is positively invariant
and adsorbing. Thus, since in H: x′ ≥ xφ(x)(yC(xM ) − yMAXI ) > 0, it follows readily that
x(t)→ +∞;
2. It Ψ(x) > 0, it exists x¯ such that f(x¯) = 0 , y′C(x) < 0 and there is a unique LAS equilibrium
point S = (xe, ye) , then S is GAS. Proof: Let us define y
MAX
I := Maxx∈[0,x]yI(x) and
yminI := Minx∈[0,x]yI(x). Furthermore, if f(0) > y
MAX
I let it be x˜ = y
−1
I (y
MAX
I ), if f(0) ≤
yMAXI let it be x˜ = 0. Since Ψ(x)(y
min
I − y) ≤ y′ ≤ Ψ(x)(yMAXI − y) it is easy to see that
the set R =
{
(x, y)|x˜ < x ≤ x AND yminI ≤ y ≤ yMAXI
}
is positively invariant and adsorbing
and contains S. Since we have ruled out the possibility that there may be limit cycles, as a
consequence S is GAS.
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3. When Ψ(x) > 0 and y′C(x) is non-constant and there is a unique LAS equilibrium point S =
(xe, ye), if it holds also that
yMaxC > y
Max
I (16)
then S is GAS. Proof: When f(x) is unbounded, one may see that, there may be a relative
minimum followed by a relative maximum in (0, x). On the contrary, when f(x) is bounded,
there is an absolute maximum. Calling now x∗ the point in which yC(x) is (absolutely or
relatively) maximum, one has that R∗ =
{
(x, y)|x∗ ≤ x ≤ x AND yminI ≤ y ≤ yMAXI
}
is
positively invariant and adsorbing, contains S. Since in R∗ it is y
′
C(x) ≤ 0 ( which implies that
closed orbits are ruled out), as a consequence, S must be GAS.
4. When Ψ(x) > 0 and yI(x) > yC(x) for x ∈ [0, x¯] then CF is GAS. Proof: It is a particular
case of proposition 2.
5. If Ψ(x) > 0, there does not exist a x¯ such that f(x¯) = 0 , y′C(x) < 0 and there is a unique
LAS equilibrium point S = (xe, ye) , then S is GAS. Proof: Let us define y
MAX
I :=
Maxx∈[0,+∞)yI(x). Let us consider a point Po = (xo, 0) with xo > xe, and the orbit start-
ing from it, which intersects the curve yC(x) in the point Pa = (xa, yC(xa)). Let us consider the
following points Pb = (xa, y
MAX
I ), Pc = (0, y
MAX
I ) and Pd = (0, 0). The arc of orbit P̂oPa and
the straight segments PaPb,PbPc,PcPd and PdPo bounds an invariant set for our system. As a
consequence of the Bendixon-Poincare’ tricothomy we have that S is GAS.
6. When Ψ(x) has variable sign, and f(x) is bounded and yI(x) > yC(x) then CF is GAS. Proof:
the set X =
{
(x, y)|0 < x ≤ x AND y ≥ 0
}
is positively invariant and adsorbing and in it closed
orbits are impossible, as we have seen. However it is not a bounded set, so we have to show that
all the orbits starting in X are bounded. Firstly, we notice that it cannot be y(t)→ +∞, since
in such a case, being x′ = x(αf(x)−y(t)), it would be x(t)→ 0⇒ y(t)→ σ/Ψ(0). Furthermore
hypothetical solutions such that minlimt→+∞ y(t) = 0 and Maxlimt→+∞ y(t) = +∞ are not
possible since the set A =
{
(x, y)|0 < x ≤ x1 AND y ≥ yc(x)
}
is positively invariant. As a
consequence of these properties, thanks to the Bendixon-Poincare’ trichotomy, CF is GAS.
7. When Ψ(x) has variable sign, there is x¯ such that f(x¯) = 0, yC(x) < 0 and there is a unique
LAS equilibrium point S then S is GAS. Proof: the set X =
{
(x, y)|0 < x ≤ x AND y ≥ 0
}
is positively invariant and adsorbing and in it closed orbits are impossible, as we have seen.
However it is not a bounded set. Let us consider yI(x): it is such that it is split in two branches:
yrightI (x) for x2 ≤ x ≤ +∞ (which has no intersections with yC(x)) and yleftI (x) for 0 ≤ x < x1
(on which S lies). Let us consider a point Pi = (xi, yi) lying on the curve (x, y
right
I (x)) and
having yi > yC(0) > yC(x2). Let the orbit starting from Pi intersect the graph (x, y
left
I (x)) in
a point Pf = (xf , yf ) = (xf , y
left
I (xf )) (note that it is yf > yi). Let us define the following
points: PA = (0, yf ), PB = (0, x¯) and PC = (x¯, yi). It is easy to see that segment of orbit P̂iPf
and the straight segments PfPA,PAO, OPB , PBPC and PCPi bound an invariant set Ω for our
dynamical system. As a consequence, thanks to the Bendixon-Poincare trichotomy, S is GAS.
8. When the sign of Ψ(x) is variable, there is no x¯ such that f(x¯) = 0, yC(x) < 0 and there is
a unique LAS equilibrium point S then S is GAS. Proof: The proof is easily obtained by
applying methods of propositions 7 and 5 to find a bounded positively invariant set surrounding
S.
9. When Ψ(x) > 0 and q(x) = 0 then ∀(x(0), y(0)) it is y(t) → 0+. Furthermore, in accordance
with the growth law f(x), either the tumor tends to an equilibrium value or it grows unbounded.
Proof: Let us define Ψmin = minx∈R+Ψ(x). If q(x) = 0 it is y
′ = −Ψ(x)y ≤ Ψmin ⇒ y(t)→
0+. Thus, the equation for x(t) becomes asymptotically autonomous, so that, depending on
f(x), either x(t)→ +∞ or x(t)→ x¯ (i.e. in this case the equilibrium IF = (x¯, 0) is GAS).
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10. When Ψ(x) > 0 and f(x) = 1 and φ(x) = const = ϕ, and there are two equilibria S = (xe, ye)
(LAS) and U = (xu, yu) (unstable) and there is a separatrix curve y = Σ(x) which does not join S
to U, then there are two sets A and B such that if (x(0), y(0)) ∈ A then (x(t), y(t))→ S, whereas
if (x(0), y(0)) ∈ B then x(t) → +∞. Proof: Let us define yMAXI := Maxx∈R+yI(x) and
xΣ = Σ
−1(yMAXI ) . As a consequence, the set A =
{
(x, y)|0 < x < xΣ AND Min(0,Σ(x)) ≤
y ≤ yMAXI
}
is positively invariant and in it there are no closed orbits, so if (x(0), y(0)) ∈ A
then (x(t), y(t)) → S. It is easy to show that given a yI(xΣ)/ϕ < % < α/ϕ also the set
B =
{
(x, y)|x > xΣ AND 0 ≤ y ≤ %
}
is positively invariant. Thus, since in B: x′ ≥ x(α − %),
it easily follows that x(t)→ +∞;
11. Let it be Ψ(x) > 0, y′c(x) ≤ 0 and it exists x¯ such that yC(x¯) = 0 Let there be 4 equilibria CF
(unstable), Sl = (xe, ye) (LAS), U = (xu, yu) (unstable) and Sr = (xe, ye) (LAS), and let there
be a separatrix curve y = Σ(x) which does not join Sl or Sr to U, then there are two sets A and B
such that if (x(0), y(0)) ∈ A then (x(t), y(t))→ Sl, whereas if (x(0), y(0)) ∈ B then (x(t), y(t))→
Sr. Proof: As in the previous proposition A =
{
(x, y)|0 < x < xΣ AND Min(0,Σ(x)) ≤ y ≤
yMAXI
}
is positively invariant and in it there are no closed orbits, so if (x(0), y(0)) ∈ A then
(x(t), y(t)) → Sl. In this case B =
{
(x, y)|0 < x < x¯ AND 0 ≤ y ≤ Min(Σ(x), yMAXI )
}
,
and it is positively invariant as well, and with no closed orbits in it. As a consequence: if
(x(0), y(0)) ∈ B then (x(t), y(t))→ Sr ;
Remark A consequence of the fourth proposition is that if y′I(0) > 0 (or y
′
I(0) = 0 AND y
′′
I (0) > 0)
then σ > σcr is a sufficient condition for the GAS of the CF equilibrium.
In case of multiple equilibria with φ(x) = const it may be useful to transform (8)-(9) to a nonlinear
oscillator. In fact by setting z = Log(x) it is easy to see that the original family becomes:
z′′ + (ψ¯(z)− f¯ ′(z))z′ + ϕσq¯(z)− ψ¯(z)f¯(z) = 0 (17)
where ψ¯(z) = ψ(Ez) etc. . . By defining the damping coefficient:
2ν(z) = (ψ¯(z)− f¯ ′(z)) (18)
and the pseudo-potential:
U(z) =
∫ z
0
(
ϕσq¯(s)− ψ¯(s)f¯(s)
)
ds (19)
and the total pseudo-energy:
Etot =
(z′)2
2
+ U(z) (20)
it follows immediately that when ν(z) > 0:
• Let it be x¯ < +∞ and let there be three equilibria zl < zc < zr which are, respectively LAS,
unstable and again LAS. Let it be Etot(0) < U(zc), then z(0) < zc ⇒ z(t) → zl, whereas
z(0) > zc ⇒ z(t)→ zr;
• Let it be x¯ = +∞ and let there be two equilibria zl < zc which are, respectively LAS and
unstable. Let it be Etot(0) < U(zc), then z(0) < zc ⇒ z(t) → Zl, whereas z(0) > zc ⇒
z(t)→ +∞.
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3 On immunotherapies
3.1 Therapy schedulings
A realistic anticancer therapy may be modeled with sufficient approximation as constant (e.g. via a
constant intravenous infusion) or periodic (e.g. the agent is delivered each day as a bolus):
θ(t) = θm + Ω(t) ≥ 0, θ(t+ T ) = θ(t), θm = 1
T
∫ T
0
θ(t)dt (21)
For humans, typical periods ranges between 8 hours to 7 days [9, 5]. A particular case of periodic
therapy is pulsed therapy, i.e. a therapy which induces an instantaneous increase of the number of
lymphocytes:
θ(t) = γ
+∞∑
n=0
δ(t− nT ) (22)
In the case of constant infusion therapy (CIT) (θ(t) = θm) by defining:
σ̂ := σ + θm, q̂(x) :=
σ + θm
σ̂
(23)
Remark In the next subsections some asymptotic analyses of therapies shall be conducted. The
meaning of the underlying t → +∞ limits is the following: the therapies are administered for a time
interval [0, tf ] which is finite but sufficiently high to guarantee that the number of cancer cells is zero
or that other targets have been reached.
3.2 Continuous infusion therapy
All the considerations we have done the absence of therapy hold also in case of CIT. In particular, for
f(0) < +∞, the condition for the LAS of the cancer-free equilibrium is:
σ + θm > σcr (24)
Because of the co-presence of other equilibria, the above criterion is not global, i.e. the immunotherapy
is not able to guarantee the disease eradication from whatever initial values (x(0), y(0)). However,
observing that in models in which Ψ(x) > 0:
ywiththerapyI (x) =
σq(x) + θm
Ψ(x)
> ynotherapyI (x) (25)
(e.g. in Stepanova’s model with low µ1) it happens that, roughly speaking, the stable equilibrium size
of the cancer becomes smaller and the unstable equilibria greater, so that the basin of attraction of
the unbounded solution is reduced.
Let us consider now some typical situations in case of y′C(x) < 0:
• Non aggressive tumor (i.e. Ψ(x) ≤ 0 in [x1, x2]). In such a case, in absence of therapy there
may be in the most complex case 4 equilibria: CF (unstable), a small tumor equilibrium Eomicro
(LAS), a macroscopic equilibrium EOMACRO (LAS) and an intermediate unstable equilibrium
EOU , as in figure 1-subplot 1. E
o
micro is determined by the intersection between yC(x) and the
branch ylI(x), E
o
MACRO and E
o
U by the intersection between yC(x) and y
l
I(x). Increasing θ there
are new equilibria. For θ > θcf = yc(0)− yI(0) CF becomes at least LAS and Emicro disappear.
On the right, as a consequence of the elementary properties of continuous decreasing functions,
increasing θ the equilibria move and it is xEu(θ) > xEu(0), xEMACRO (θ) < xEMACRO (0), and
there exists θr ∈ (0, yrI (xEu)− yrC(xEMACRO )) such that for θ > θr EMACRO and EU disappear.
Summarizing, when θ > θ˜ = Max(θcf , θr) then CF is GAS (figure 1-subplot 3), because of
proposition 4 of section 2.1. If θr < θcf then for θr < θ < θcf Emicro is GAS (figure 1-subplot
2), whereas when θcf < θr for θcf < θ < θr CF is LAS and coexists with EU and EMACRO(figure
2);
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• Aggressive tumors with variable sign Ψ′(x). In such a case, in the absence of therapy there may
in the most complex case be one macroscopic equilibrium equilibrium: EoMacro (GAS) and, of
course, CF (unstable). Increasing θ two further equilibria may appear. The analysis is similar
to the previous one (cfr figures 3 and 4) and we may find a θ˜ such that for θ > θ˜ CF is GAS.
Note that when the tumor is aggressive it is very likely that θ˜ is ”extremely high”: θ˜ >> σ;
• Aggressive tumors with Ψ′(x) < 0 [17]. In such a case, in the absence of therapy there may in
the worst case be one macroscopic equilibrium equilibrium: EoMacro (GAS) and, of course, CF
(unstable). Increasing θ, if when yI(0) = yc(0) it is y
′
I(0) < y
′
C(0) then we may find two values
θcf and θ˜ > θcf such that for θcf < θ < θ˜ CF is LAS and there is the birth of a third unstable
equilibrium Eu. Finally for θ > θ˜ CF is GAS. Note that if when yI(0) = yc(0) it is y
′
I(0) > y
′
C(0)
then θcf = θ˜.
When f(0) = +∞ the total elimination cannot be achieved by immunotherapy alone. Furthermore,
even the suboptimal target of reducing the cancer to a microscopic size in many relevant cases cannot
be achieved for therapies of finite duration, however they may be long. In fact, let it be Ψ(x) > 0
(aggressive tumor) and let there be a unique GAS macroscopic equilibrium EMACRO. By applying
a CIT with θ sufficiently high there is a unique GAS microscopic equilibrium. However, when the
therapy ceases θ falls to zero and the cancer restarts growing macroscopically, since EMACRO is again
GAS. We note in brief that if the original equilibrium is microscopic (e.g. micrometastasis) the effect
of the therapy is simply to create another and temporary microscopic equilibrium.
Let us suppose that there are three co-existing equilibria: Eomicro (LAS), E
o
U (Unstable and through
which a separatrix Σo passes) and EoMACRO (LAS). Applying a CIT with θ > θ˜ there is an unique
GAS microscopic equilibrium. Thus at the end of the therapy (at t = tf ) depending on the position
of Pf = (x(tf ), y(tf )) relatively to Σ
o, we have that either (x(t), y(t)) → Emicro or (x(t), y(t)) →
EMACRO.
We note that θ acts a global bifurcation parameter, and we point out that these behavior may be
observed in case of bounded f(0) when therapy is applied for an insufficient time.
Finally, this simple analytical analysis may explain theoretically some numerical results of [15]
on the relationships between the efficacy of the cure and the proliferation rate of cancer, and on the
correlation between the burden of initial size and the probability of effectiveness of a therapy.
3.3 Periodic Scheduling
In the case of periodic drug schedulings, there is a periodically varying cancer-free solution CF ∗ =
(0, z(t)), where z(t) is the asymptotic periodic solution of:
y′ = −Ψ(0)y + σ + θm + Ω(t) (26)
that, assuming Ω(t) =
∑+∞
n=1 CkCos(k(2pi/T )t− ζn), can be rewritten as::
z(t) =
σ + θm
Ψ(0)
+
+∞∑
n=1
Ck√
Ψ2(0) + k2( 2piT )
2
Cos(k
2pi
T
t− ζn −Arg(Ψ(0) + ik 2pi
T
)). (27)
Note that if T << 1/Ψ(0) there is a filtering effect and z(t) ≈ (σ + θm)/Ψ(0).
Two basic models of therapy may be:
•
θu(t) = A(1 + bcos(ωt)) (28)
which is rather unrealistic, but whose functional form is commonly used to assess the effect of
periodic forcing on nonlinear systems. The asymptotic solution of (26) corresponding to (28) is
given by:
zu(t) =
σ +A
Ψ(0)
+
Ab√
Ψ2(0) + ω2
Cos(ωt−Arg(Ψ(0) + iω))
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• the more realistic function:
θr(t) =
G
1− Exp(−cT )Exp(−cMod(t, T )) , θm =
G
cT
, (29)
which represent a boli-based delivery. The ”shape” of θr(t) depends on c and the corresponding
asymptotic periodic solution of (26) is given by:
zr(t) =
σ
Ψ(0)
+
G
Ψ(0)− c
(E−cMod(t,T )
1− E−cT −
E−Ψ(0)Mod(t,T )
1− E−Ψ(0)T
)
In case of impulsive therapy, by solving the impulsive differential equation
y′ = −Ψ(0)y + σ, y(nT+) = y(nT−) + γ, n = 0, 1, . . . (30)
one obtains that:
z(t) =
σ
Ψ(0)
+
γ
1− Exp(−Ψ(0)T )Exp
(
−Ψ(0)Mod(t, T )
)
. (31)
Furthermore, it is easy to show that the condition σ + θm > σcr guarantees the LAS of CF . In
fact, since the variational equations around (0, z(t)) are: U ′ = (αf(0) − φ(0)z(t))U,W ′ = (σq′(0) −
Ψ′(0)z(t))U −Ψ(0)W , we obtain that αf(0)− φ(0) < z(t) >< 0⇒ U(t)→ 0⇒W (t)→ 0, and since
< z(t) >= (σ+θm)/Ψ(0) we recover the LAS condition σ+θm > σcr. Similarly, one may demonstrate
the GAS condition: σ + θm > σ
∗.
3.4 Numerical simulations
We performed a set of simulations of immunotherapy on the basis of the model proposed by Kuznetsov
et al. [14], in which:
αf(x) = 1.636(1− 0.002x), φ(x) = 1, β(x) = 1.131x
20.19 + x
, σq(x) = 0.1181
µ(x) = 0.00311x+ 0.3743,
and
ttrue = 9.9tadimdays, (X,Y ) = 106(x, y)cells
We chose this model since its parameter values were fitted from real data of chimeric mice [14].
Note that the dynamic of tumors in mouse is faster than that of human tumors, and that for periods of
about one day or less (i.e. T < 0.101) it results that (1/µ(0)) >> T . Moreover, µ′(x) = 0.00311 << 1
and the tumor is not aggressive. We also performed simulations in a case of a more aggressive tumor,
for which we set µ(x) = 10(0.00311x) + 0.3743. For the non-aggressive tumor σcr ≈ 0.612 and
σ∗ ≈ 1.44 >> σ.
It is worth noticing that in other kinds of anticancer therapies the shape of the therapy may be
critical in determining whether or not the cancer will be eradicated [8].
In our simulations we assumed σ + θm > σcr which means that the mean value of the therapy,
if given as CIT, would enassure the LAS of the disease free equilibrium. Since for each T the mean
value is constant, this means that in the limit c→ +∞ the therapy θr(t) tends to become impulsive.
We found that:
• In the absence of therapy: non-aggressive tumor has two stable equilibria: one slightly less than
the carrying capacity and the other corresponding to a small tumor (see phase portrait in figure
5). For the highly aggressive tumor there is one GAS equilibrium slightly less than the carrying
capacity;
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• With constant therapy: the non-aggressive tumor has a cancer-free equilibrium, which results
to be GAS (figure 6). Note that the orbits stemming from initial points characterized by low
values of the number of immune system cells are characterized by an initial rapid growth of the
tumor size, followed by a regression to 0. Biologically, the therapy might seem to help the tumor
growth, instead of fighting it. For the highly aggressive tumor, the cancer free equilibrium is
LAS, but there is also a high size LAS equilibrium (7);
• In the presence of periodic therapy with θr(t), for both types of tumors the phase portrait is
roughly similar to that of the constant therapy: the cancer-free periodic solution remains GAS
for the non aggressive tumor (figure 8). For the aggressive tumor there is the coexistence of
the cancer free solution with a solution fluctuating around high values of the cancer size (near
the equilibrium of the constant therapy). The two basins of attraction for the aggressive tumor
remain unvaried with respect to those of the constant therapy (figure 9).
• For θr(t) the dependence of the qualitative properties of the system on the parameter c is not
critical.
• For aggressive tumor and θu(t), it may occur that, given an initial point, the eradication is
also a function of parameters b and ω, but this happens only for unrealistically high values
of the therapy period (figure 10), e.g. T > 100 days. These results may be roughly explained
considering that for T >> Max(1/Ψ(0), 1/α), one may approximately consider θu(t) as constant;
• Both with CIT and with periodic therapy y(t) may reach values considerably higher than the
physiological value σ/µ(0), which might model some serious side effects of immunotherapies due
to the excess of immunocompetent cells [4, 5].
For the sake of completeness, we also performed some simulations in which 0 < A < σcr − σ and
for which there were high oscillations (b = 1). We obtained the result that for low frequencies, there
may be points in the (ω,A) plane for which eradication is possible. See fig. (11).
Finally, we performed simulations for a hybrid model similar to that by Kuznetsov et al. [14], but
in which we assumed:
α = 0.626, f(x) = Log(
500
x
),
the other parameters being as before. We choose the value α = 0.626 in order to minimize the difference
with f(x) in [14]. The results of the simulations are very close to those relative to the logistic case:
figures 12, 13. In order to obtain via CIT the reduction to the microscopic state θ > 8.4σ about is
required.
The analytical and numerical results obtained in this section may be usefully compared with two
similar works of the recent literature which focus on Adoptive Cellular Immunotherapy. An excellent
analytical work is [19], who, however, cannot be fully compared with our results because it refers to
tumors which have no action in stimulating immune cells. Furthermore, its formulae for the global
stability of the cancer free equilibrium are not expressed as a function of the parameters of the therapy.
In a very interesting paper [16] some results similar to ours are obtained through numerical bifurcations
on a three dimensional model in which the direct immunogenicity of tumors is expressed as an additive
term cx. As previously stressed, in the absence of therapy and of influx of immunocompetent cells
both our model and the model in [16] show the possibility of having periodic solution, which in [16]
are shown to be present also in some cases in which there is therapy. We notice in brief that a term
cx may be formally embedded in our generic function σ(x).
4 Concluding Remarks
It is interesting to use well established conceptual frameworks of ecological models to model com-
petition phenomena in human biology, but it is important to pay attention to the whole ecological
modeling aspect, such as the basic requirement of the positivity of the solutions. Even if model [22]
violates the positivity rule, it is valuable because it may be read as a model which takes into account
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a disease-induced depression in the influx of lymphocytes. Then, instead of proposing another specific
model, we preferred to add this new feature to a family of equations, and to analyze its properties. We
stressed also that models which do not allow the possibility to have LAS tumor-free solutions should
be cautiously considered. The general family (8)-(9) may be, of course, further generalized following
Volterra’s ecological theory, i.e. by considering that there may be a delay between the consumption
of a prey and the birth of a predator (see also [15, 20, 21]), i.e. by allowing a delay τ with probability
density %(τ). This delayed model and stochastic models will be the subject of further investigations.
Finally, we would like to illustrate some qualitative medical inferences from the investigations that
we have here proposed. The main problem of immunotherapy is that, as it is clear from our analysis
and simulations, in general, eradication may be possible but is dependent on the initial conditions
(x(0), y(0)). However, the IC are in medical practice unknown or known with very large confidence
intervals (cfr. [59] for the cancer cells at the start of a radiotherapy and). This makes it impossible
to plan an anticancer therapy based solely on this therapy. This is a peculiarity of immunotherapy,
since there are other kinds of anticancer cures for which a globally stable eradication is possible [8].
However, in our simulations we have seen that in some particular cases the model [14] predicts that
globally stable eradication is possible also in case of immunotherapy, but that it depends on the
”degree of aggressiveness” of the cancer, i.e., on the framework of the model [14], on the parameter
µ1. However, µ1 is difficult to be estimated (as a range) and, in particular, on single patients. If in
the future it might be possible, the option to use immunotherapy as main strategy, for relatively small
”non aggressive” tumors, could be seriously considered. Furthermore, we showed that the behavior of
the system does not depend on the amplitude of fluctuations of θ(t), so that the option of continuous
intravenous infusion is not, dynamically, better than the boli based therapy. This result may be of
interest, since continuous intravenous infusion may cause major practical problems to the patients.
Finally, in case of disease aggressive towards the immune system, since our simulations indicated
that all the positive quadrant is GAS towards a macroscopic disease in absence of therapy and low
σ, whereas in the presence of therapy the eradication is possible in an adequate basin (see figure
7), we may infer that a conventional therapy should be followed by immunotherapy to increase the
probability of total remission.
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Figure 1: Illustration of the effect of a CIT on a typical configuration in a lowly aggressive tumor. The
case is shown in which θr < θcf . yI(x) is plotted as a solid line, whereas yc(x) is dashed. The equilibria
are plotted as black points and they are labeled U when unstable, otherwise S. First subfigure: figure:
in the absence of therapy there are four equilibria among which CF. Second subfigure: with a therapy
with θr < θ < θcf CF is unstable and coexists with a microscopic tumor equilibrium which is GAS.
Fourth subfigure: for a high dose therapy θ > θcf CF becomes GAS.
Figure 2: Illustration of the effect of a CIT in a low aggressive tumor for θcf < θr and θcf < θ < θr.
Symbols as in figure 1
16
Figure 3: Illustration of the effect of a CIT in an aggressive tumor for increasing values of the CIT.
Figure 4: Illustration of the effect of a CIT in an aggressive tumor, similar to figure 3, but with LAS
CF coexisting with two other equilibria (θcf ”low”).
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Figure 5: Non aggressive tumor: phase portrait of model [14] in the absence of therapy. There are two
LAS equilibria, whose basins of attraction are separated by the separatrix line (plotted with a thick
line). The nullcline yC(x) is plotted with short dashes, the nullcline yI(x) and its vertical asymptotes
are plotted with long dashes.
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Figure 6: Non aggressive tumor: phase portrait of model [14] in the presence of constant therapy
with σ + θm = 1.1σcr. There is a tumor-free equilibrium CF = (0, 1.799), which is globally stable.
The nullcline yC(x) is plotted with short dashes, the nullcline yI(x) and its vertical asymptotes are
plotted with long dashes. Note that the orbits stemming from initial points characterized by low y(0)
are characterized by an initial fast growth of the tumor size, followed by a regression to 0.
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Figure 7: Aggressive tumor: phase portrait of model [14] in presence of constant therapy. There is
a tumor-free equilibrium CF = (0, 1.799) and another LAS equilibrium, whose basins of attraction
are divided by a separatrix line (plotted with a thick line). The nullcline yC(x) is plotted with short
dashes, the nullcline yI(x) and its vertical asymptotes are plotted with long dashes.
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Figure 8: Non aggressive tumor: phase portrait of model [14] in presence of periodic therapy θr(t)
with T = 0.202 (=2 days) and 1/c = 0.1T . There is a tumor free equilibrium (0, z(t)) ≈ (0, 1.799)
which remains GAS. The nullcline yC(x) is plotted with short dashing, the nullcline yI(x) and its
vertical asymptotes are plotted with long dashes.
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Figure 9: Aggressive tumor: phase portrait of the model [14] in the presence of periodic therapy
with T = 0.202 (=2 days) and 1/c = 0.5T . The basins of attraction of the tumor-free equilibrium
CF ∗ = (0, z(t)) ≈ (0, 1.799) and of the macroscopic size equilibrium remain near unchanged respect to
the CIT scheduling (the basin of CF is slightly greater than in the CIT). The nullcline yC(x) is plotted
with short dashing, the nullcline yI(x) and its vertical asymptotes are plotted with long dashes.
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Figure 10: Aggressive tumor in the presence of immunotherapy θu(t): growth behavior in function of
the parameters (ω, b). Black points correspond to eradication, white points to macroscopic growth.
The initial condition for all is (40, 2.5) (chosen near the separatrix for the constant therapy). Left:
σ+A = 1.01σcr, central: σ+A = 1.1σcr and right: σ+A = 1.25σcr. Note that the frequencies which
do not allow eradication are very low, corresponding to absolutely unrealistic periods for the therapy.
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Figure 11: Aggressive tumor in the presence of immunotherapy θu(t): growth behavior in function
of the parameters (ω,A) for b = 1, with A < σcr − σ. Black points correspond to eradication, white
points to macroscopic growth. The initial condition for all is (40, 2.5) (chosen near the separatrix for
the constant therapy).
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Figure 12: Simulation of the modified Kutnetsov model with CIT and θm = 0.5σ.
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Figure 13: Simulation of the modified Kutnetsov model with periodic therapy, T = 0.202 (2 days),
1/c = 0.5T and θm = 6σ.
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